We identified 243 patients with Ph-positive CML who had BCR-ABL transcripts monitored by quantitative RT-PCR after allogeneic stem cell transplant for a median of 84.3 months.
INTRODUCTION
It is generally accepted that chronic myeloid leukemia (CML) begins when a single hematopoietic stem cell acquires a BCR-ABL fusion gene in association with a Philadelphia (Ph) chromosome, and this leads in due course to inappropriately regulated expansion of the myeloid tissue in the body. At least in some patients there is evidence that the lymphoid lineage is also involved at an early stage. Without effective treatment the chronic phase progresses inexorably to an advanced phase which ultimately proves fatal. Allogeneic stem cell transplantation (SCT) was first used to treat patients with CML in chronic phase (CP) in the early 1980s (1-4); with clinical experience over 25 years it is clear that some patients have survived for long periods post-transplant without evidence of relapse and may be regarded as 'cured' (5), although the mechanism underlying such 'cures' is not well defined. Moreover occasional patients who were treated by allogeneic stem cell transplant in chronic phase have relapsed more than 10 years after an otherwise 'successful' transplant (6,7) and data collated by the Center for International
Blood and Marrow Transplant Research show that the cumulative incidence of relapse at 15 years for patients in remission at 5 years after matched sibling transplants for CML in chronic phase was 17% (8) . Thus the issue whether some or conceivably all patients continue to harbor in their body small quantities of residual leukemia after allo-SCT remains open.
We started in 1990 to monitor CML patients who received an allogeneic SCT at the The data also provide a basis for speculating about the possible significance of the survival of BCR-ABL-positive 'stem' cells in some patients after allografting.
PATIENTS AND METHODS

Patients
We identified a cohort of 243 patients with Ph chromosome positive CML who had received an allogeneic SCT in chronic or advanced phase between November 1981 and Informed consent was provided in accordance with the Declaration of Helsinki.
Transplant procedure
All patients received conventional conditioning pre-transplant with high dose cyclophosphamide and total body irradiation (4, 11, 12) ; patients treated with nonmyeloablative conditioning were excluded from this analysis. The stem cell donors were HLA-identical siblings (n=129), HLA-matched (n=106) or mismatched (n=5) unrelated volunteers or phenotypically HLA-matched family members (n=3) ( Table 1 ). In-vivo T-cell depletion with alemtuzumab (CD52 antibody) followed by cyclosporine and methotrexate was used was as graft-versus-host disease (GvHD) prophylaxis in 114 transplants (106 from alternative donors) (12) and cyclosporine and methotrexate alone were used in 114 cases, of which 111 were sibling transplants. Ex vivo T-cell depletion was undertaken in 11 procedures (6 siblings, 5 alternative donors). Cyclosporine alone as GvHD prophylaxis was used in 4 sibling transplants. In 93 procedures both donor and recipient were males; 46 transplants involved male patients with female donors, 60 transplants involved female patients with male donors and 44 procedures involved female patients with female donors. Acute GvHD was classified according to criteria proposed by Glucksberg et al (13) ; chronic GvHD when present was categorized as limited or extensive.
Measurement of BCR-ABL transcript numbers
All patients had BCR-ABL transcript numbers measured by Q-PCR on at least 5 occasions during follow-up in the period starting 6 months post-transplant (median number of measurements 26, range 5 to 55). 20ml of heparinized peripheral blood was collected from each patient and a cell pellet prepared following red cell lysis. Total RNA was extracted from the guanidine thiocyanate (GTC) cell lysate containingmercaptoethanol. Until 1997 the total RNA was extracted using the cesium chloride ultracentrifuge method as previously reported (14) . Thereafter total RNA was isolated by ion-exchange chromatography using a commercially available kit (Qiagen, Crawley, UK) in accordance with the manufacturer's instructions. The cDNA was synthesized using random hexamers as previously described (9, 15) .
All cDNA with BCR-ABL transcripts undetectable by multiplex PCR was subjected to nested primer PCR as previously reported (9) . Until 2000 the cDNA samples positive by nested primer PCR were then subjected to competitive PCR for BCR-ABL and ABL quantification as reported previously (9, 15) . Since 2000 BCR-ABL and ABL transcripts in cDNA were measured by realtime Q-PCR following multiplex PCR (Taqman, Applied Biosystems, Foster City, CA). This assay detects e13a2 (b2a2) and e14a2 (b3a2) transcripts in a single reaction. The BCR-ABL transcript quantification was performed in triplicate to minimize sampling error. The ABL RQ-PCR was performed in duplicate. A standard curve was generated for each assay using serial dilutions of linearized plasmid containing a BCR-ABL insert. Hence the same plasmid was used for quantification of BCR-ABL and ABL, which should control for any variation in plasmid quantitation efficiency between BCR-ABL and ABL.
Definitions of molecular relapse
We have previously established criteria to define molecular relapse (MR) in patients who were monitored by Q-PCR after allogeneic SCT. We suggested originally that therapeutic intervention might not be required for patients with transcript levels below 100 µg/RNA (16) which is equivalent to a BCR-ABL/ABL ratio of 0.02% (17) . Subsequently we suggested that a patient should be regarded as in molecular relapse if his or her BCR-ABL/ABL ratio remained at or exceeded a level thought to reflect a level approximately 50-fold lower than that seen in early MR (18); the criteria we adopted were designed to avoid classifying as relapse the occasional patient who had fluctuating low levels of BCR-ABL transcripts. Thus the criteria for MR used in this study were specified in 2001 (19): A patient satisfied criteria for MR if they had (i) three PCR results over a minimum period of 4 weeks with a BCR-ABL/ABL ratio in excess of 0.02%, or (ii) two results over a minimum period of four weeks higher than 0.05%. The finding of a positive PCR within the first 6 months after allogeneic SCT was not regarded as indicating relapse and so such results were discounted. Any patient who did not achieve relapse at the molecular, cytogenetic or hematologic level was regarded as remaining in molecular remission.
Administration of donor lymphocyte infusions (DLI)
Patients who met criteria for relapse were considered for treatment by donor lymphocyte infusion (DLI) if lymphocytes from the original transplant donor were available and if the patient was not undergoing treatment for extensive GvHD. Lymphocytes were administered as a single bulk dose until 1995 and thereafter on an escalating dose schedule (20,21).
Comparison of nested primer PCR and realtime quantitative PCR (RQ-PCR).
We considered it important to compare results obtained with RQ-PCR with those obtained with nested primer PCR. We therefore used nested primer PCR to quantitate BCR-ABL transcripts in cDNA samples determined to have between 0 to 10 copies by real time PCR and we used Q-PCR to measure transcripts in cDNA samples that were negative by nested PCR. Only those samples with control ABL copies >1x10 4 in the same volume of cDNA used to detect BCR-ABL were included in these comparisons, thus limiting the comparison to specimens with high fidelity RNA. Samples with <1.0 BCR-ABL copies by Q-PCR were reported as negative. In each case 5 µl of cDNA was used.
Statistical methods
The probabilities of relapse and disease progression were calculated using the cumulative incidence procedure. Curves were compared using the log-rank test.
RESULTS
Patient outcome post-transplant
For this patient population the median follow-up post-transplant was 84.3 months (range 15-271). 220 patients were alive at the time of this analysis, while 23 patients have died.
The primary cause of death was leukemia relapse or progression in 12 cases, GvHD in 8 cases, infection in 1 case and secondary malignancies in 2 cases.
Patterns of BCR-ABL transcripts after SCT
The patterns of serial BCR-ABL transcript numbers differed appreciably in the 243 patients included in this study. 114 patients remained in molecular remission, of whom some never had transcripts detectable and others on one occasion only. Some patients had transcripts detectable intermittently only at low levels. Some patients had transcripts
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From detected 'persistently' at low levels. 129 patients were classified as having relapsed. We were thus able to classify individual patients into one of four major categories. (Table 2) . Of these 129 patients 115 (89.1%) proceeded to receive DLI. Fourteen patients had not received DLI at the time of this analysis, of whom 6 maintained stable transcript levels over a median period of 102 months after MR diagnosis despite having received no specific treatment. The median time from transplant to relapse was 9.8 months (range 1.1-93.2). The median times to relapse for patients transplanted in chronic and advanced phases were 10.6 months (range 2.3 to 93.2) and 3.7 months (range 1.1 to 14.3) respectively.
Influence of graft-versus-host disease
The incidence of serious acute GvHD (Grades 2 to 4) was relatively high (60%) in patients categorized as 'persistently negative' and relatively low (33%) in those classified as 'persistently positive' (p=0.039, Table 2 ). However, there was no discernible relationship between incidence of chronic GvHD and the pattern of transcript numbers 
Events after diagnosis of relapse and results of administering DLI
Of the 129 patients who satisfied our criteria for relapse, 117 were in chronic phase and 12 were in advanced phases at time of transplant. Of the 107 patients who were diagnosed with MR, 72 showed evidence of progression to cytogenetic relapse (or its molecular equivalent, see below) or hematological relapse either prior to or after starting treatment with DLI. The projected incidence of progression at 5 years from recognition of MR was 70.5% ( Figure 3) . In 26 out of the 72 patients, cytogenetic relapse was not documented by bone marrow analysis and a BCR-ABL ratio 2% was taken to be equivalent to cytogenetic relapse (17) . Forty-five patients had Ph-positive marrow metaphases identified before initiation of DLI and 28 had hematologic features of CML (Table 3 ). Progression of the 72 patients into cytogenetic relapse occurred at a median of 5.9 months (range 1.0 to 49.2). Thirty-five patients did not progress beyond molecular relapse. Of these, 28 received DLI with 15 regaining molecular remission (defined as 2 consecutive studies with undetectable BCR-ABL transcripts), 11 continue in molecular relapse without further progression and in 2 patients insufficient follow-up data are available. Seven patients were not treated in any way for leukemia for a variety of reasons.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Prior to 1997 DLI was given in a single "bulk" dose which contained variable numbers of CD3+ T cells; after 1995 an escalating dose regimen was used (21). Because in most cases arrangements had to be made to collect lymphocytes from the original transplant donor it was not usually possible to administer DLI immediately after the recognition of molecular relapse. In practice DLI was initiated at a median of 9.4 months (range 1-72 months) from relapse.
One hundred fifteen patients received DLI. 73 patients (63%) went into molecular remission post DLI with 2 consecutive negative PCR results. 27 patients (23%) are early in follow up but 10 of them have at least 1 negative PCR result. 12 patients (10.4%) have had no response and of these 9 have died while 3 are alive and currently receiving alternative treatment. In 3 cases (2.6%) there were not enough data to assess their response.
Comparison of nested primer PCR and RQ-PCR.
Our data show that of 216 samples negative by nested PCR, 51.9% were positive by RQ-PCR, whilst only 6.3% of samples negative by RQ-PCR were positive by nested PCR (Table 4 ). This would suggest that in our laboratory, the RQ-PCR is more sensitive than nested primer PCR, though the clinical significance of these low copy numbers is presently unclear. Furthermore, these data suggest that it might be inappropriate to report samples with 1 to 10 BCR-ABL copies by realtime Q-PCR as negative or undetectable, particularly if the endogenous control gene copy number is within acceptable limits.
DISCUSSION
Leukemia-specific transcripts may be detected in the blood and bone marrow of individual CML patients for some months following allogeneic stem cell transplant (9,22,23) and their level may predict the risk of relapse (24,25). Thus we showed previously that patients with no BCR-ABL transcripts detected between 3 and 5 months post transplant had a probability of relapse at 3 years of 16.7%, whereas patients with low level and relatively high transcripts levels had risks of relapse of 42.9% and 86% respectively (25). When patients were categorised at 5 years post-transplant on the basis of prior transcript pattern, the subsequent risk of relapse was related to the transcript pattern in the interval preceding the 5 year point (19). However, we observed some patients who had transcripts detectable at low level for long periods after SCT without obvious progression. Because we did not know the clinical significance of finding these transcripts at low level, we were reluctant to regard them as having relapsed and thus in need of further therapy. We therefore proposed criteria for MR designed to exclude patients in whom transcripts were present only at low levels, regardless of how long such low levels might persist (19).
We show in this paper that patients who fail to satisfy our criteria for MR during prolonged periods of observation can be classified into three categories, some persistently negative for BCR-ABL transcripts, some intermittently positive at low level and some persistently positive at low level. There was a significant relationship between the allocated category of transcripts and incidence of acute GvHD (grades 2 or more). Of the patients who did eventually achieve MR some could be categorised on the basis of their transcript pattern before relapse; those persistently positive at low level were significantly more likely to relapse than those who were persistently negative, and for those intermittently positive before relapse the risk was intermediate. 
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The relationship between incidence of aGVHD and the pattern of persistent low level molecular positivity is significant (p=0.039, chi-squared trend test), but the relationship between pattern of cGVHD and pattern of molecular disease shows no significant relationship (p=0.71). 
P=0.0085
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